Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Imatinib mesilate (Glivec) is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients are one of the COVID-19 risk groups. Moreover, imatinib target mechanism of action, which is effective in cancer, can have a high potential against the most severe COVID-19 complication such as the disease associated pulmonary fibrosis. COVID-19 associated interstitial pulmonary fibrosis develops as an autoimmune process caused by systemic inflammation with atypical (idiopathic) pneumonia resulting from acute respiratory distress syndrome with the tyrosine kinase mechanism of signaling pathway activation and cellular response. Experimental and clinical results showing antifibrotic and dose-related antithrombotic imatinib effect demonstrate perspective use of this antitumor agent to correct COVID-19 associated pneumonia causing a high death rate of patients with COVID-19.The review presents literature data of 2001–2020 discussing pathologic genetic and clinical characteristics of the fibrosis which exacerbates COVID-19 pneumonia in adults. The sequence of the disease processes demonstrates that disease progression with the decreasing oxygen saturation in the peripheral blood intensifies local thrombosis in the lungs. As a result, hypoxia is developing, which is difficult to control and can cause lethal outcome in severe cases. Yet, the conventional antifibrotic and thrombolytic agents can only partially control the process of pneumofibrosis including that of cancer patients. The approximate antifibrotic dose of imatinib 400 mg / day is therapeutic for oncopathology. The antitumor drug registered in many countries and well described side effects and contraindications needs no long-term registration studies for a new indication, therefore, it may be easily prepared for clinical testing.
Imatinib mesilate (Glivec) is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients are one of the COVID-19 risk groups. Moreover, imatinib target mechanism of action, which is effective in cancer, can have a high potential against the most severe COVID-19 complication such as the disease associated pulmonary fibrosis. COVID-19 associated interstitial pulmonary fibrosis develops as an autoimmune process caused by systemic inflammation with atypical (idiopathic) pneumonia resulting from acute respiratory distress syndrome with the tyrosine kinase mechanism of signaling pathway activation and cellular response. Experimental and clinical results showing antifibrotic and dose-related antithrombotic imatinib effect demonstrate perspective use of this antitumor agent to correct COVID-19 associated pneumonia causing a high death rate of patients with COVID-19.The review presents literature data of 2001–2020 discussing pathologic genetic and clinical characteristics of the fibrosis which exacerbates COVID-19 pneumonia in adults. The sequence of the disease processes demonstrates that disease progression with the decreasing oxygen saturation in the peripheral blood intensifies local thrombosis in the lungs. As a result, hypoxia is developing, which is difficult to control and can cause lethal outcome in severe cases. Yet, the conventional antifibrotic and thrombolytic agents can only partially control the process of pneumofibrosis including that of cancer patients. The approximate antifibrotic dose of imatinib 400 mg / day is therapeutic for oncopathology. The antitumor drug registered in many countries and well described side effects and contraindications needs no long-term registration studies for a new indication, therefore, it may be easily prepared for clinical testing.
INTRODUCTION: In 2020, humanity faced a pandemic of a new infection a Severe Acute Respiratory Syndrome-related Corona Virus 2 (SARS-CoV-2) that had a significant impact on the economic, social, including medical, aspects of our life. Against the background of these changes, oncological diseases, like many other comorbid pathologies, seemed to fade into insignificance. But, as we understand, they have not lost their relevance, but only ‘retreated to the shadow’ for a while. Study of the basic statistical indicators used for evaluating the prevalence of cancer pathology and the results of the work of oncological service, helps analyze and understand the processes occurring in conditions of reorientation of medical measures for combating the pandemic. AIM: To study changes in the main indicators of the oncology service of the Ryazan region during the COronaVIrus Disease 2019 (COVID-2019) epidemic. MATERIALS AND METHODS: The main statistical indicators of morbidity, detestability and mortality from malignant neoplasms (MNs) in the Ryazan region were analyzed on the basis of statistical forms of federal statistical observation No. 7 (Form No. 7) ‘Record of MNs’, reports and data of cancer registry for 2012–2022. The most relevant statistical indicators were analyzed, data on most common and relevant tumor localizations were separately considered. RESULTS: At the height of COVID-19 pandemics in 2020–2021, a sharp reduction of the total number of identified MN cases was observed a seeming decline of ‘mortality’. At the same time, there was an increase in the proportion of patients with advanced IV stage pathology of lungs, stomach, and colorectal cancer, which, in turn, led in some cases to increase in one-year mortality, and to general increase in mortality among cancer patients. To note, despite a complicated situation associated with non-observance of the terms of the periodic medical examinations, reprofiling of a number of medical organizations and increased load on the primary medical care organizations, the oncology service of the Ryazan region showed a not that catastrophic impairment of the main statistical indicators, and of some of them a proportion of detection of early stages, results of treatment of tumors of visual localization even a positive dynamics. In 2022, officially registered cancer incidence rates in our region returned to previous values comparable to 2019. CONCLUSION: The experience of recent years should help in developing measures to prevent both the spread of similar epidemiological diseases and measures to prevent a decline of the quality of specialized medical care, in particular, in the field of oncology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.